Upadacitinib

Rinvoq approval bolsters AbbVie's autoimmune portfolio
Rinvoq approval bolsters AbbVie's autoimmune portfolio
BioCentury
AbbVie
FDA
Rinvoq
Upadacitinib
rheumatoid arthritis
Flag link:
Four New Drugs are Around the Corner. Here’s What You Need to Know.
Four New Drugs are Around the Corner. Here’s What You Need to Know.
Xconomy
FDA
drug approvals
AbbVie
Upadacitinib
Exondys 51
Sarepta Therapeutics
Nabriva Therapeutics
lefamulin
Roche
Rozlytrek
Flag link:
Watch out AbbVie: Gilead is fast on your heels at the FDA with rival JAK inhibitor filgotinib
Watch out AbbVie: Gilead is fast on your heels at the FDA with rival JAK inhibitor filgotinib
Endpoints
Gilead Sciences
AbbVie
FDA
JAK inhibitors
filgotinib
Upadacitinib
rheumatoid arthritis
Flag link:
3 Drugs Under FDA Review With Blockbuster Potential
3 Drugs Under FDA Review With Blockbuster Potential
Motley Fool
AbbVie
Upadacitinib
rheumatoid arthritis
Novartis
brolucizumab
wet age-related macular degeneration
Celgene
ozanimod
relapsing multiple sclerosis
Flag link:
Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
Motley Fool
Alexion
Ultomiris
AbbVie
Upadacitinib
risankizumab
Aimmune Therapeutics
AR-101
Bluebird Bio
LentiGlobin
Flag link:
4 Blockbuster Drug Launches to Watch in 2019
4 Blockbuster Drug Launches to Watch in 2019
Motley Fool
drug launches
AbbVie
Alexion Pharmaceuticals
Aimmune Therapeutics
Skyrizi
psoriasis
Upadacitinib
rheumatoid arthritis
Ultomiris
PNH
AR101
peanut allergy
Flag link:
Forget Humira -- Here's What You Need to Know About AbbVie
Forget Humira -- Here's What You Need to Know About AbbVie
Motley Fool
AbbVie
Humira
Upadacitinib
risankizumab
Rick Gonzalez
Flag link:
AbbVie rheumatoid arthritis drug succeeds in late stage trial
AbbVie rheumatoid arthritis drug succeeds in late stage trial
Yahoo/Reuters
AbbVie
clinical trials
rheumatoid arthritis
Upadacitinib
Flag link:
A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis
A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis
Yahoo/Motley Fool
AbbVie
Gilead Sciences
FDA
rheumatoid arthritis
Upadacitinib
filgotinib
Flag link:
3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate
3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate
Yahoo/Motley Fool
AbbVie
Huimra
Upadacitinib
rheumatoid arthritis
Flag link:
AbbVie to submit upadacitinib to FDA after 5th trial win
AbbVie to submit upadacitinib to FDA after 5th trial win
Fierce Pharma
AbbVie
Upadacitinib
rheumatoid arthritis
FDA
JAK inhibitors
Flag link:
Up-and-coming Pfizer, AbbVie drugs set to threaten Amgen, Celgene: analyst
Up-and-coming Pfizer, AbbVie drugs set to threaten Amgen, Celgene: analyst
Fierce Pharma
Pfizer
Xeljanz
AbbVie
Upadacitinib
JAK inhibitors
Amgen
Enbrel
Celgene
Flag link:
AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study
AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study
CP Wire
AbbVie
rheumatoid arthritis
Upadacitinib
clinical trials
Flag link:
With study success, AbbVie's arthritis hopeful looks to be a safer bet
With study success, AbbVie's arthritis hopeful looks to be a safer bet
Biopharma Dive
AbbVie
rheumatoid arthritis
Upadacitinib
Humira
clinical trials
Flag link:
AbbVie Presents New Data on Upadacitinib for Crohn's Disease
AbbVie Presents New Data on Upadacitinib for Crohn's Disease
Yahoo/Zacks.com
AbbVie
Upadacitinib
Crohn's Disease
Flag link:
These 3 Drugs Are Critical to AbbVie's Success
These 3 Drugs Are Critical to AbbVie's Success
Motley Fool
AbbVie
Rova-T
Upadacitinib
risankizumab
Flag link:
ABBV to Focus on Advancing Late-Stage Immunology Research in 2018
ABBV to Focus on Advancing Late-Stage Immunology Research in 2018
Market Realist
AbbVie
R&D
immunology
Upadacitinib
risankizumab
Flag link:
Why AbbVie's Upadacitinib Keeps Posting Strong Data for Rheumatoid Arthritis
Why AbbVie's Upadacitinib Keeps Posting Strong Data for Rheumatoid Arthritis
Market Realist
AbbVie
Upadacitinib
rheumatoid arthritis
Flag link:
Another death mars AbbVie’s latest batch of promising data for its star rheumatoid arthritis drug
Another death mars AbbVie’s latest batch of promising data for its star rheumatoid arthritis drug
BioPharma Dive
AbbVie
rheumatoid arthritis
Upadacitinib
ABT-494
Flag link:
AbbVie keen on JAK inhibitor despite safety concerns
AbbVie keen on JAK inhibitor despite safety concerns
BioPharma Dive
AbbVie
JAK inhibitors
Upadacitinib
ABT-494
rheumatoid arthritis
Flag link:

Pages